Compare EFOI & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EFOI | BLRX |
|---|---|---|
| Founded | 1985 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 12.9M |
| IPO Year | 1994 | 2011 |
| Metric | EFOI | BLRX |
|---|---|---|
| Price | $2.25 | $2.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 19.2K | ★ 23.2K |
| Earning Date | 11-12-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,863,000.00 | ★ $12,735,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.19 | $2.30 |
| 52 Week High | $3.56 | $14.70 |
| Indicator | EFOI | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.12 | 39.72 |
| Support Level | $2.30 | $2.85 |
| Resistance Level | $2.57 | $3.03 |
| Average True Range (ATR) | 0.29 | 0.17 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 35.05 | 18.39 |
Energy Focus Inc engages in the design, development, manufacturing, marketing, and sale of energy-efficient lighting systems and controls. The company serves the military maritime market and general commercial markets. Its product offerings include Military maritime LED lighting products such as military intelligible, globe lights, berth lights, and military fixtures and Commercial products such as LED fixtures and panels, LED down-lights, LED dock lights, and LED retrofit kits. Geographically, it operates in the United States and other countries. Its products include commercial products and MMM products. The company generates a majority of its sales from Military maritime products in the United States.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.